Two-year outcomes following PSMA PET and MRI guided prostate SABR with simultaneous focal boost: a brief report from the ARGOS-CLIMBER phase 1/2 trial.

Alayed Y; Loblaw A; Mendez LC; Correa RJM; Dhar A; Laidley D; Warner A; Fakir H; Wronski M; Conyngham J; Kassam Z; Helou J; D'Souza DP; Velker V; Lock M; Ahmad B; Bauman GS.

doi:10.1016/j.radonc.2026.111786

15 Sept 2026📖 Free full textPeer-ReviewedPubMedResearch ArticleTherapeuticDiagnosticRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026

Two-year outcomes following PSMA PET and MRI guided prostate SABR with simultaneous focal boost: a brief report from the ARGOS-CLIMBER phase 1/2 trial.

Alayed Y, Loblaw A, Mendez LC, Correa RJM, Dhar A, Laidley D (+11 more)

📖 Read the full paper (free)doi:10.1016/j.radonc.2026.111786 →

Abstract

ARGOS-CLIMBER is a phase 1/2 trial evaluating PSMA PET and MRI guided prostate SABR with a simultaneous boost to intraprostatic and nodal disease in men with unfavourable intermediate and high-risk prostate cancer. The updated results demonstrate acceptable safety and quality of life with high biochemical and imaging response rates.